A team of investigators from the [b]University of Pennsylvania[/b] have found that the opioid antagonist naltrexone may be an effective treatment for diminishing impulse control disorders (ICDs) in patients with Parkinson’s disease (PD).
Researchers say ICDs can create financial, personal, employment, and social problems that add to the burden on patients and caregivers whose lives are already devastated by PD. Lead author, Dr Daniel Weintraub, a fellow in [b]Penn’s Institute on Ageing[/b]. says however, that the outcome of the eight-week study was not definitive.
[link url=http://www.uphs.upenn.edu/news/News_Releases/2014/07/weintraub]University of Pennsylvania press release[/link]
[link url=http://www.neurology.org/content/early/2014/07/18/WNL.0000000000000729.short?sid=25fcf5cb-bbf1-4a27-95d5-e747ab63ca4b]Neurology abstract[/link]